Development and external validation of a nomogram for individualized adjuvant imatinib duration for high‐risk gastrointestinal stromal tumors: A multicenter retrospective cohort study

Abstract Introduction The main emphasis of the research about adjuvant imatinib for high‐risk gastrointestinal stromal tumors (GISTs) is prolonging the treatment duration and ignores the heterogeneous that 10‐year recurrence rates ranged from about 20%–100%. Thus, this study evaluated the effect of...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ruolin Liu, Yingxin Wu, Jin Gong, Rui Zhao, Li Li, Qianyi Wan, Nan Lian, Xiaoding Shen, Lin Xia, Yuhou Shen, Haitao Xiao, Xiaoting Wu, Yi Chen, Ying Cen, Xuewen Xu
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2022-08-01
Saila:	Cancer Medicine
Gaiak:	adjuvant imatinib gastrointestinal stromal tumors high risk individualized treatment duration
Sarrera elektronikoa:	https://doi.org/10.1002/cam4.4673
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!